Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology

Rhea-AI Summary

A new scientific article in the US journal Clinical Pharmacology in Drug Development validates Xspray Pharma's HyNap™ technology. The study shows improved bioavailability and reduced variability for two tyrosine kinase inhibitors (TKIs): Dasynoc™ (XS004, dasatinib) and XS005 (sorafenib).

Key findings include:

• Dasynoc™: Bioequivalence at 30% lower dose, with up to 4.8 times less variation in plasma exposure
• XS005: 45% increase in absorption and up to 2.8 times less variability in plasma exposure

These improvements could lead to better safety and potentially increased treatment effectiveness for cancer patients. The publication in a peer-reviewed journal confirms the HyNap technology's potential to enhance both efficacy and safety in cancer treatment.

Positive

• Scientific validation of HyNap technology in a leading US journal
• Dasynoc achieves bioequivalence at 30% lower dose
• Dasynoc shows up to 4.8 times less variation in plasma exposure
• XS005 demonstrates 45% increase in absorption
• XS005 exhibits up to 2.8 times less variability in plasma exposure
• Potential for improved safety and treatment effectiveness in cancer patients

Negative

• None.

Medical Research Analyst

This publication in a peer-reviewed journal significantly validates Xspray Pharma's HyNap™ technology. The improved bioavailability and reduced variability of Dasynoc™ (dasatinib) and XS005 (sorafenib) are crucial advancements in cancer treatment. The ability to achieve bioequivalence at lower doses (30% for dasatinib) with up to 4.8 times less variation in plasma exposure is remarkable. For sorafenib, the 45% increase in absorption and 2.8 times less variability are equally impressive.

These improvements could lead to:

• Enhanced treatment efficacy
• Reduced side effects
• Better patient compliance
• Potentially lower treatment costs

The fact that Xspray's formulations are not affected by gastric acid-reducing agents further broadens their clinical applicability. This scientific validation could pave the way for wider adoption of Xspray's technology in oncology drug development.

Financial Analyst

This scientific endorsement is a significant milestone for Xspray Pharma, potentially boosting investor confidence. The HyNap™ technology's proven benefits could lead to:

• Increased market share in the lucrative oncology drug market
• Potential licensing opportunities with major pharmaceutical companies
• Enhanced competitive advantage in drug formulation

However, it's important to note that while scientific validation is important, it doesn't guarantee immediate commercial success. Investors should monitor:

• Regulatory approvals and timelines
• Partnerships or licensing deals
• Market adoption rates
• Competition in the space

The reduced variability and lower dosage requirements could translate to cost savings for healthcare systems, potentially driving demand. Overall, this publication strengthens Xspray's position in the pharmaceutical landscape.

STOCKHOLM--(BUSINESS WIRE)-- A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap™ technology improves the bioavailability and reduces variability of two important tyrosine kinase inhibitors (TKIs), Dasynoc™ (XS004, dasatinib) and XS005 (sorafenib). Reduced variability generally leads to better safety and can potentially increase treatment effectiveness for patients, ensuring prescribers that their seriously ill patients consistently receive the prescribed dose.

The article, entitled “Enhanced Oral Bioavailability and Reduced Pharmacokinetic Variability of Dasatinib and Sorafenib through Hybrid Nanoparticle-Amorphous Solid Dispersion Technology,” highlights that Xspray's amorphous drug formulations achieve bioequivalence at lower doses and with less variability in uptake and thus plasma exposure compared to crystalline reference products. These new data in several hundred people, together with a previous study showing that Xspray's amorphous dasatinib products are not affected by gastric acid-reducing agents, are major improvements for clinical use.

Key findings presented in the article:

• Dasynoc™ (XS004, dasatinib): Bioequivalence at 30% lower dose, with up to 4.8 times less variation in plasma exposure compared to the reference product.
• XS005 (sorafenib): 45% increase in absorption and up to 2.8 times less variability in plasma exposure compared to the reference product.

The publication in a peer-reviewed journal confirms the HyNap technology's potential to improve both efficacy and safety in the treatment of cancer patients.

Per Andersson, CEO of Xspray Pharma, comments: “It is significant that our research is recognized in a leading American scientific journal. The publication confirms HyNap technology's ability to improve drug solubility and bioavailability, which we believe will lead to better treatment outcomes and fewer side effects especially for chronically medicated cancer patients.”

https://doi.org/10.1002/cpdd.1416

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906133856/en/

For more information, please contact:

Per Andersson, CEO Xspray Pharma AB

Tel: +46 8 730 37 00

Email: info@xspraypharma.com

Source: Xspray Pharma

FAQ

What are the key findings of the Xspray Pharma (XSPRAY) study published in Clinical Pharmacology in Drug Development?

The study shows that Xspray's HyNap technology improves bioavailability and reduces variability of two TKIs: Dasynoc (dasatinib) achieves bioequivalence at 30% lower dose with up to 4.8 times less variation, and XS005 (sorafenib) shows 45% increase in absorption and up to 2.8 times less variability in plasma exposure.

How does Xspray Pharma's (XSPRAY) HyNap technology potentially benefit cancer patients?

The HyNap technology could lead to better safety and potentially increased treatment effectiveness for cancer patients by improving drug solubility and bioavailability, which may result in better treatment outcomes and fewer side effects, especially for chronically medicated patients.

What advantages does Dasynoc (XS004) from Xspray Pharma (XSPRAY) offer compared to the reference product?

Dasynoc (XS004) achieves bioequivalence at a 30% lower dose and shows up to 4.8 times less variation in plasma exposure compared to the reference product, potentially leading to improved safety and efficacy for patients.

What improvements does Xspray Pharma's (XSPRAY) XS005 (sorafenib) demonstrate over the reference product?

XS005 (sorafenib) shows a 45% increase in absorption and up to 2.8 times less variability in plasma exposure compared to the reference product, which could result in more consistent and effective treatment for patients.